The Washington Post has taken a look at how hospitals are using genetic tumor databases to find exceptional responders to cancer drugs. Such patients, the handful in a large trial who respond far better to a treatment than the rest, have always existed but researchers lacked the tools to learn why they were outliers. Tumor sequencing has provided the tools and the Post featured profiles of several people whose care has improved because of the approach. The challenge now is to see whether the discoveries can be scaled to benefit more patients. Feature (sub. req.)